the product in the database has an inactive status
indications:
Prevention of influenza, especially in people who have a higher risk of post-influenza complications.
Composition:
1 dose of 0.5 ml contains inactivated viral surface antigens corresponding to the following strains: A (H3N2) - 15 μg, A (H1N1) - 15 μg and B - 15 μg.
Action:
Vaccine. The protective level of antibodies is usually obtained within 2-3 weeks. The vaccine immunity is usually maintained for 6-12 months.
Contraindications:
Hypersensitivity to the components of the preparation, egg, chicken protein, polymyxin B or neomycin. Do not give intravascularly.
Precautions:
Vaccination should be postponed in case of diseases involving fever or acute infections. The response to vaccination may be insufficient in patients with endogenous or iatrogenic immunosuppression.
Pregnancy and lactation:
Caution use in the second and third trimester of pregnancy, however, in pregnant women with conditions that increase the risk of post-influenza complications, it is recommended to use the vaccine regardless of the stage of pregnancy. The preparation can be used during breastfeeding.
Side effects:
Common: redness, swelling, pain, bruising or hardening at the injection site, fever, feeling unwell, chills, tiredness, headache, increased sweating, pain in the muscles and joints; symptoms usually disappear after 1-2 days. Uncommon: generalized skin reactions (pruritus, urticaria, non-specific rash). Rare: neuralgia, paraesthesia, convulsions, transient thrombocytopenia, hypersensitivity reactions leading to anaphylactic shock. Very rare: vasculitis with transient renal involvement, neurological disorders (encephalomyelitis, neuritis, Guillain-Barré syndrome).
Dosage:
Intramuscularly or deeply subcutaneously. Adults and children from 36 months: 0.5 ml. If children have not previously been vaccinated against influenza, the second dose should be given at least 4 weeks after the first vaccination.
(C)
